Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

Abstract

A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics of the tyrosine kinase inhibitor nintedanib, alone and when added to ongoing pirfenidone therapy, in Japanese patients with idiopathic pulmonary fibrosis. 50 Japanese patients were randomised to receive nintedanib or placebo in one of three cohorts (nintedanib 50 mg twice daily or 100 mg twice daily for 14 days, or 150 mg twice daily for 28 days). Patients receiving pirfenidone at inclusion were stratified to every nintedanib dose group and placebo. Adverse events were reported in nine out of 17 patients receiving nintedanib alone and 10 out of 21 patients receiving nintedanib added to pirfenidone. All adverse events were mild or moderate in intensity. Gastrointestinal disorders were the most common adverse event. Maximum plasma concentration and area under the curve at steady state for nintedanib and its metabolites tended to be lower when nintedanib was added to pirfenidone. Nintedanib had no effect on the pharmacokinetics of pirfenidone. In conclusion, further study is needed to evaluate the safety and tolerability profile of nintedanib when added to pirfenidone in patients with idiopathic pulmonary fibrosis. There was a trend toward lower exposure of nintedanib when it was added to pirfenidone.

Overview

Integrity signals

Registry

Crossref · 10.1183/09031936.00198013

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Pulmonary Physiology Specialist Committee of the Japanese Respiratory Society, 2001, Predicted values of spirometry and arterial blood gas analysis in Japanese, J Jpn Respir Soc, 39, 1

Cited by

See all 225

Metadata

Authors
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Klüglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., & Sugiyama, Y.
Affiliations
  • Kanagawa Cardiovascular and Respiratory Center (JP)
  • Tosei General Hospital (JP)
  • Nippon Medical School (JP)
  • NHO Kinki Chuo Chest Medical Center (JP)
  • Nagoya University (JP)
  • Jichi Medical University (JP)
  • Himeji Medical Center (JP)
  • Hamamatsu University School of Medicine (JP)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (Japan) (JP)
Venue
European Respiratory Journal
Published
2014-12-10
Volume
45
Issue
5
Pages
1382-1392
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2146127863
Cited by
215
References
18
Citations by year
2026: 6 · 2025: 8 · 2024: 16 · 2023: 16 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 18 · 2018: 27 · 2017: 28 · 2016: 21 · 2015: 22
FWCI
18.95
Type
journal article
Language
en
Open access
closed
Locations
  • European Respiratory Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
nintedanib, pirfenidone, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, pharmacokinetics, drug safety and tolerability, adverse events, gastrointestinal adverse effects, drug-drug interactions, Japanese patients
MeSH terms
Aged, Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Japan, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/09031936.00198013
The paper
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Klüglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., & Sugiyama, Y. (2015). Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00198013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.